Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Garcia

Showing results (381-390 of 455) with videos related to

Pageof 46
Sort By:
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|September 29, 2025
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised TrialErika Bonacina, Mireia Armengol-Alsina, Pablo Garcia-Manau, et al.
Journal of the American College of Cardiology|November 11, 2025
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label TrialNeal K Lakdawala, Ray E Hershberger, Pablo Garcia-Pavia, et al.
Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.
JACC. Clinical Electrophysiology|May 10, 2024
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic CardiomyopathyFrancisco J Bermudez-Jimenez, Alexandros Protonotarios, Soledad García-Hernández, et al.
Plos One|August 4, 2017
Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathyIrene Mademont-Soler, Jesus Mates, Raquel Yotti, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
European Heart Journal|March 20, 2026
Genetic counselling implementation in dilated cardiomyopathyJob A J Verdonschot, Karin Y van Spaendonck-Zwarts, Debby M E I Hellebrekers, et al.
Nature Metabolism|March 15, 2022
Angiocrine polyamine production regulates adiposityErika Monelli, Pilar Villacampa, Amaia Zabala-Letona, et al.
Pageof 46

Showing results (381-390 of 455) with videos related to

Sort By:
Pageof 46
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|September 29, 2025
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised TrialErika Bonacina, Mireia Armengol-Alsina, Pablo Garcia-Manau, et al.
Journal of the American College of Cardiology|November 11, 2025
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label TrialNeal K Lakdawala, Ray E Hershberger, Pablo Garcia-Pavia, et al.
Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.
JACC. Clinical Electrophysiology|May 10, 2024
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic CardiomyopathyFrancisco J Bermudez-Jimenez, Alexandros Protonotarios, Soledad García-Hernández, et al.
Plos One|August 4, 2017
Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathyIrene Mademont-Soler, Jesus Mates, Raquel Yotti, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
European Heart Journal|March 20, 2026
Genetic counselling implementation in dilated cardiomyopathyJob A J Verdonschot, Karin Y van Spaendonck-Zwarts, Debby M E I Hellebrekers, et al.
Nature Metabolism|March 15, 2022
Angiocrine polyamine production regulates adiposityErika Monelli, Pilar Villacampa, Amaia Zabala-Letona, et al.
Pageof 46